In A375 melanoma cells, 20 nM LY2090314 increased total β-catenin and Axin2 protein in a 0–8 h immunoblot time course. This qualitative downstream response does not quantify cellular target occupancy. [1]
In lorlatinib-intermediate-resistant JFCR-028-3 derivatives, adding 30 nM LY2090314 lowered viability relative to lorlatinib alone after 72 h. The parental cells showed no reported change in lorlatinib sensitivity with the combination, demonstrating model-dependent activity. [2]
Recombinant GSK3 inhibition
Biochemical assay · Human recombinant GSK3α and GSK3β in a cell-free peptide-substrate assay [1]
Reported IC50 values establish nanomolar enzyme inhibition; they are assay endpoints rather than cell-treatment concentrations.
Literature-Reported Treatment Conditions
- Method
- Recombinant enzyme plus phosphorylated peptide substrate; method refers to Engler et al. (2004).
- Reported limits
- The 2015 assay paragraph does not specify the concentration series, ATP concentration, incubation duration, vehicle, replicate count or normalization/control details. Referenced 2004 full text was not retrieved; no conditions were borrowed.
Methods and source locations
Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314
Evidence concerns the named compound and reported experimental material; no Adooq lot or formulation validation.
Materials and Methods: GSK3 biochemical assay; Results sec017, first paragraph; Fig 1A
Human recombinant GSK3α inhibition: Cell-free recombinant kinase assay with a phosphorylated peptide substrate. — Results sec017, first paragraph
Human recombinant GSK3β inhibition: Same reported assay framework, tested with the β isoform. — Results sec017, first paragraph
Protein response to LY2090314 in A375 melanoma cells
Cell-based study · A375 human melanoma cells [1]
A time-course immunoblot showed increased total β-catenin and Axin2 protein after LY2090314 exposure relative to the zero-time sample.
Literature-Reported Treatment Conditions
- Treatment concentration
- 20 nM
- Exposure duration
- 0, 0.5, 1, 2, 4 and 8 h, as labeled in Fig 1C
- Method
- Cell treatment followed by immunoblotting.
- Co-treatment
- Single-agent LY2090314
- Reported limits
- Fig 1C does not state an independent replicate count or quantified uncertainty; vehicle identity for this panel is not specified. Zero-time is the depicted comparator, not a stated time-matched vehicle series.
Methods and source locations
Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314
Evidence concerns the named compound and reported experimental material; no Adooq lot or formulation validation.
Fig 1C image/caption; Results sec017; Materials and Methods: Immunoblotting and Reagents
Total β-catenin and Axin2 protein abundance: Western blot with GAPDH loading control and zero-time comparison. — Fig 1C image/caption and Results sec017
LY2090314 plus lorlatinib in parental and resistant lung cancer cells
Cell-based study · JFCR-028-3 parental cells and lorlatinib-intermediate-resistant derivatives LR1000#1, LR1000#2 and LR3000 [2]
Adding a fixed concentration of LY2090314 to lorlatinib lowered viability in resistant derivatives relative to lorlatinib alone. The authors reported no difference in lorlatinib sensitivity in parental cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- LY2090314 fixed at 30 nM with a lorlatinib concentration series, as labeled in Fig 3b–e.
- Exposure duration
- 72 h
- Method
- CellTiter-Glo luminescence viability assay; cells seeded in triplicate.
- Vehicle
- DMSO used to dissolve LY2090314 and lorlatinib; final vehicle percentage not specified in the read section.
- Co-treatment
- LY2090314 plus lorlatinib, compared with lorlatinib alone.
- Reported limits
- Caption identifies three replicates without establishing independent biological repeats. Exact potency estimates and combination statistics are not tabulated for these panels.
Methods and source locations
Compound reported in the paper: LY2090314; Compound label in the paper: LY2090314
Supplier attribution supports reported AdooQ use, without establishing SKU or lot equivalence.
Fig 3b–e image/caption; Results Sec4; Methods: Reagents and Cell viability assay
Relative cell viability (% of control): CellTiter-Glo after 72 h; no numerical IC50 or exact curve values inferred. — Fig 3b–e image/caption; Results Sec4